1. Scrip
  2. >>R&D
  3. >>Clinical Trials

ADA: Zepbound Could Take Sleep Apnea Patients Off CPAP

 
• By Elizabeth Cairns

Lilly’s incretin looks set to add obstructive sleep apnea to its label – an indication in which Novo Nordisk has so far shown no interest.    

Eli Lilly logo sign - San Diego, California, USA - 2020
• Source: Shutterstock/Michael Vi

Eli Lilly and Company’s incretin drug tirzepatide is playing catch-up to Novo Nordisk A/S’s semaglutide in many disorders. In obese patients with obstructive sleep apnea, however, it is ahead of the competition, and new data from the pivotal SURMOUNT-OSA trial suggest that tirzepatide might amount to a cure in some of these patients.

Key Takeaways
  • New SURMOUNT-OSA data show that Lilly’s tirzepatide allowed some obese obstructive sleep apnea patients to have resolution of the condition.
  • The benefit seems to be solely driven...

SURMOUNT-OSA had been toplined a hit on its primary endpoint in April, with tirzepatide at either 10mg or 15mg for one year significantly reducing patients’ scores on the apnea-hypopnea index...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from R&D

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.